Adenocarcinoma
|
0.010 |
GeneticVariation
|
group |
LHGDN |
We identified thirteen loci showing significant differential DNA methylation levels between tumor and non-tumor lung; eight of these show highly significant hypermethylation in adenocarcinoma: CDH13, CDKN2A EX2, CDX2, HOXA1, OPCML, RASSF1, SFPR1, and TWIST1 (p-value < 0.0001).
|
17967182 |
2007 |
Brain Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
This study demonstrates that OPCML down-regulation occurs in the majority of brain tumours tested, warranting further investigation of OPCML and other IgLONs in the development and progression of brain tumours.
|
17239010 |
2007 |
Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated OPCML expression in nonneoplastic brain tissue and 35 brain tumours (18 glioblastoma multiformes, five anaplastic gliomas, five meningiomas, six metastases and one medulloblastoma) and four glioma cell lines using quantitative reverse transcriptase polymerase chain reaction (RT-PCR).
|
17239010 |
2007 |
Glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated OPCML expression in nonneoplastic brain tissue and 35 brain tumours (18 glioblastoma multiformes, five anaplastic gliomas, five meningiomas, six metastases and one medulloblastoma) and four glioma cell lines using quantitative reverse transcriptase polymerase chain reaction (RT-PCR).
|
17239010 |
2007 |
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using the current tissue collection and 5-fold cross validation, the four most significant loci (CDKN2A EX2, CDX2, HOXA1 and OPCML) individually distinguish lung adenocarcinoma from non-cancer lung with a sensitivity of 67-86% and specificity of 74-82%.
|
17967182 |
2007 |
Malignant neoplasm of lung
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Using the current tissue collection and 5-fold cross validation, the four most significant loci (CDKN2A EX2, CDX2, HOXA1 and OPCML) individually distinguish lung adenocarcinoma from non-cancer lung with a sensitivity of 67-86% and specificity of 74-82%.
|
17967182 |
2007 |
Adult Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated OPCML expression in nonneoplastic brain tissue and 35 brain tumours (18 glioblastoma multiformes, five anaplastic gliomas, five meningiomas, six metastases and one medulloblastoma) and four glioma cell lines using quantitative reverse transcriptase polymerase chain reaction (RT-PCR).
|
17239010 |
2007 |
Childhood Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated OPCML expression in nonneoplastic brain tissue and 35 brain tumours (18 glioblastoma multiformes, five anaplastic gliomas, five meningiomas, six metastases and one medulloblastoma) and four glioma cell lines using quantitative reverse transcriptase polymerase chain reaction (RT-PCR).
|
17239010 |
2007 |
Glioblastoma Multiforme
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated OPCML expression in nonneoplastic brain tissue and 35 brain tumours (18 glioblastoma multiformes, five anaplastic gliomas, five meningiomas, six metastases and one medulloblastoma) and four glioma cell lines using quantitative reverse transcriptase polymerase chain reaction (RT-PCR).
|
17239010 |
2007 |
Secondary Neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In this study, we investigated OPCML expression in nonneoplastic brain tissue and 35 brain tumours (18 glioblastoma multiformes, five anaplastic gliomas, five meningiomas, six metastases and one medulloblastoma) and four glioma cell lines using quantitative reverse transcriptase polymerase chain reaction (RT-PCR).
|
17239010 |
2007 |
Stomach Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Comparison of gene expression profiles between primary tumor and metastatic lesions in gastric cancer patients using laser microdissection and cDNA microarray.
|
17109515 |
2006 |
Congenital contractural arachnodactyly
|
0.020 |
Biomarker
|
disease |
BEFREE |
The combined marker between OPCML and HOXD9 showed sensitivity, specificity, PPV, and NPV of 62.50%, 100%, 100%, and 72.72%, respectively, which may be helpful to prevent a misdiagnosis between CCA and other biliary diseases.
|
30832707 |
2019 |
Tumor Cell Invasion
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
We report the generation of a panel of OPCML variants with representative clinical mutations and demonstrate clear phenotypic effects in vitro and in vivo including changes to anchorage-independent growth, interaction with activated cognate receptor tyrosine kinases, cellular migration, invasion in vitro and tumor growth in vivo.
|
31316070 |
2019 |
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Immunohistochemistry results showed that the expression of OPCML in gastric cancer was 68.6% and the expression of OPCML was negatively correlated with the depth of tumor invasion and tumor differentiation degree (P < 005); OPCML expression, depth of tumor invasion, lymph node metastasis and distant metastasis were important factors affecting the prognosis of the survival of the patients (P <0.05).
|
27358143 |
2016 |
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our meta-analysis identified the correlations between a number of aberrant methylated genes (p16, RASSF1A, GSTP1, p14, CDH1, APC, RUNX3, SOCS1, p15, MGMT, SFRP1, WIF1, PRDM2, DAPK1, RARβ, hMLH1, p73, DLC1, p53, SPINT2, OPCML and WT1) and HCC.
|
27835605 |
2016 |
Carcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
The high frequency of OPCML promoter methylation in urothelial carcinomas suggests an important role for this epigenetic alteration in bladder carcinogenesis, highlighting its potential as an epigenetic biomarker for bladder urothelial carcinoma with prognostic significance.
|
21273058 |
2011 |
Congenital contractural arachnodactyly
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Low-protein expression was found in >70% of CCA with methylation of OPCML or DcR1.
|
21448164 |
2011 |
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The methylation frequencies of the ten genes examined in HCC were 40.0% for p14 ( ARF ), 60.9% for p15 ( INK4b ), 70.4% for p16 ( INK4a ), 34.8% for p73, 70.4% for GSTP1, 64.3% for MGMT, 13.0% for hMLH1, 59.1% for RARbeta, 82.6% for SOCS-1, and 80.9% for OPCML.
|
20112070 |
2010 |
Carcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation.
|
18714356 |
2008 |
Epithelial ovarian cancer
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Opioid binding protein/cell adhesion molecule-like gene (OPCML), a recently identified tumor-suppressor, is frequently inactivated by allele loss and CpG island promoter methylation in epithelial ovarian cancer.
|
16384911 |
2006 |
Epithelial ovarian cancer
|
0.020 |
Biomarker
|
disease |
BEFREE |
OPCML is frequently somatically inactivated in EOC by allele loss and by CpG island methylation.
|
12819783 |
2003 |
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Previous studies have reported that the expression of the opioid binding protein/cell adhesion molecule-like (OPCML) gene was frequently downregulated in various of types of cancer.
|
29805691 |
2018 |
Malignant neoplasm of stomach
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Down-regulated OPCML expression might serve as an independent predictor for unfavorable prognosis of patients, and the biological behavior supports its role as a tumor suppressor in gastric cancer.
|
28407749 |
2017 |
Stomach Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Down-regulated OPCML expression might serve as an independent predictor for unfavorable prognosis of patients, and the biological behavior supports its role as a tumor suppressor in gastric cancer.
|
28407749 |
2017 |
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
OPCML expression was markedly reduced in tumor tissues and cancer cell lines.
|
28407749 |
2017 |